Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in …

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the …

• Continue
• Vote Up +0 Vote Down -0You already voted!
• Read More